Mal-PEG2-Val-Cit-PABA-PNP
(Synonyms: Mal-PEG2-Val-Cit-PABA-PNP; Mal-PEG2-Val-Cit-PABA-PNP) 目录号 : GC20161Mal-PEG2-Val-Cit-PABA-PNP is a cleavable ADC linker containing two PEG units, which can be used in the synthesis of antibody-drug conjugates (ADCs) [1].
Cas No.:1345681-52-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
Mal-PEG2-Val-Cit-PABA-PNP is a cleavable ADC linker containing two PEG units, which can be used in the synthesis of antibody-drug conjugates (ADCs) [1].
Mal-PEG2-Val-Cit-PABA-PNP (CAS:1345681-52-8) is a small molecule drug that contains several functional groups. The Mal group, which is a reactive functional group, can specifically react with thiol groups on proteins. This characteristic enables the drug to target specific proteins in the body. The PEG2 group is a polyethylene glycol spacer that can enhance the solubility and stability of the drug in solution. Val and Cit groups are amino acids that help form a peptide bond, which is an essential structural component of the drug. The PABA group can be used to link the drug to other molecules, and the PNP group serves as a leaving group in chemical reactions.
This combination of Mal-PEG2-Val-Cit-PABA-PNP functional groups is designed to create a drug that can target specific proteins or biological processes in the body. For instance, the Mal group can specifically target overexpressed proteins in certain types of cancer cells, leading to more effective treatment. The PEG2 spacer can improve the pharmacokinetic properties of the drug, while the amino acid groups contribute to the drug's stability. The PABA group can be used to link the drug to other molecules such as antibodies, creating a more precise and targeted therapy.
Mal-PEG2-Val-Cit-PABA-PNP(CAS:1345681-52-8)是一种由几种功能基团组成的小分子药物。其中,Mal(马来酰亚胺)基团是一种功能基团,可以特异性地与蛋白质上的巯基发生反应,使药物能够针对特定蛋白质进行定位。PEG2基团是聚乙二醇间隔基,可以提高药物在溶液中的溶解度和稳定性。Val和Cit基团是氨基酸,用于形成肽键,是药物的重要结构组成部分。PABA基团是一种功能基团,可用于将药物与其他分子链接,而PNP基团则用作化学反应中的离去基团。
这些功能基团的组合旨在创建一种药物,可以针对身体中特定的蛋白质或生物过程。例如,Mal基团可以将药物定位到某些癌细胞中过度表达的蛋白质,从而实现更精确和有效的治疗。PEG2间隔基可以改善药物的药代动力学特性,而氨基酸基团则用于创建肽键,增加药物在体内的稳定性。PABA基团可以用于将药物与其他分子(如抗体)链接起来,以创建更加精确和针对性的治疗方案。
References:
[1]. Beck A, Goetsch L, Dumontet C, CorvaÏa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nature reviews Drug discovery. 2017 May;16(5):315-37.
| Cas No. | 1345681-52-8 | SDF | |
| 别名 | Mal-PEG2-Val-Cit-PABA-PNP; Mal-PEG2-Val-Cit-PABA-PNP | ||
| 分子式 | C34H41N7O13 | 分子量 | 755.73 |
| 溶解度 | 储存条件 | Powder: -20°C for 3 years; In solvent: -80°C for 2 years | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3232 mL | 6.6161 mL | 13.2322 mL |
| 5 mM | 0.2646 mL | 1.3232 mL | 2.6464 mL |
| 10 mM | 0.1323 mL | 0.6616 mL | 1.3232 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。